Find Buntanetap manufacturers, exporters & distributors on PharmaCompass

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Virtual Booth

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

32 Drugs in Development

32 Drugs in Development

DIGITAL CONTENT

18 NEWS #PharmaBuzz

media
18 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

32DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: (+)-phenserine, R-phenserine, 116839-68-0, (+)-posiphen, Phenserine, (+)-, Buntanetap

Molecular Formula

C₂₀H₂₃N₃O₂

Molecular Weight

337.4 g/mol

InChI Key

PBHFNBQPZCRWQP-AZUAARDMSA-N

FDA UNII

Z0O4TJ588O

Posiphen is under investigation in clinical trial NCT02925650 (Safety, Tolerability, PK and PD of Posiphen in Subjects With Early Alzheimer's Disease).

1 2D Structure

Buntanetap

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

[(3aS,8bR)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate

2.1.2 InChI

InChI=1S/C20H23N3O2/c1-20-11-12-22(2)18(20)23(3)17-10-9-15(13-16(17)20)25-19(24)21-14-7-5-4-6-8-14/h4-10,13,18H,11-12H2,1-3H3,(H,21,24)/t18-,20+/m0/s1

2.1.3 InChI Key

PBHFNBQPZCRWQP-AZUAARDMSA-N

2.1.4 Canonical SMILES

CC12CCN(C1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C

2.1.5 Isomeric SMILES

C[C@]12CCN([C@H]1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C

2.2 Other Identifiers

2.2.1 UNII

Z0O4TJ588O

2.3 Synonyms

2.3.1 MeSH Synonyms

1. N-phenylcarbamoyl Eseroline

2. N-phenylcarbamoyleseroline

3. Phenserine

2.3.2 Depositor-Supplied Synonyms

1. (+)-phenserine

2. R-phenserine

3. 116839-68-0

4. (+)-posiphen

5. Phenserine, (+)-

6. Buntanetap

7. Anvs401

8. Buntanetap [usan]

9. (+)-phenylcarbamoyleseroline

10. Anvs-401

11. Z0o4tj588o

12. (+)-o-(phenylcarbamoyl)eseroline

13. (3ar,8as)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl Phenylcarbamate

14. Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, 5-(n-phenylcarbamate), (3ar,8as)-

15. Unii-z0o4tj588o

16. Chembl4297417

17. Dtxsid001110145

18. Who 12342

19. Db15317

20. Hy-16009

21. Cs-0006062

22. [(3as,8br)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate

2.4 Create Date

2006-10-26

3 Chemical and Physical Properties

Molecular Formula	C₂₀H₂₃N₃O₂
Molecular Weight	337.4 g/mol
XLogP3	2.3
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	3
Exact Mass	337.17902698 g/mol
Monoisotopic Mass	337.17902698 g/mol
Topological Polar Surface Area	44.8 Å²
Heavy Atom Count	25
Formal Charge	0
Complexity	507
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Cholinesterase Inhibitors

Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)

Drugs in Development